Vaccines
Long dismissed as the backwaters of healthcare innovation, the tremendous value of vaccines – the single most cost-effective health intervention after clean water – made itself starkly clear in 2020, as the discovery of a novel coronavirus quickly exploded into a full-blown global pandemic that rages on still.
While billions have since been poured into vaccine development for COVID-19 and vaccine candidates have been developed and approved (albeit so far only for emergency use) at unprecedented speed, sector stakeholders are only cautiously optimistic regarding the longevity of this newly awakened global interest and investment in vaccines – and whether the frenetic zeal to discovering and deploying COVID-19 vaccines would translate into sustained and longer-term efforts to support vaccine R&D for a whole host of other infectious diseases that continue to claim tens of millions of lives annually.
This issue of InFocus dedicated to vaccines features a variety of global, regional and local stakeholders across the public and private spheres to provide a snapshot of the four thematics at the heart of the vaccine sector: Research & Development, Manufacturing & Supply Chain, Partnership Models, and Public Health Impact.
R&D: An Expanded Playbook
The story of how British doctor Edward Jenner serendipitously discovered a way to inoculate people against smallpox in 1976 by injecting them with cowpox pus is well-known. Over the past two centuries, vaccine development platforms have (thankfully) advanced leaps and bounds, delivering a wealth of options to tackle global health challenges.
Business Models & Market Access
While perhaps not as lucrative or – prior to COVID-19 – as attention-grabbing – as other areas of the pharmaceutical industry, vaccines are also not the forgotten backwaters that many industry insiders seem to view them as. While the inherent complexities related to vaccine R&D do impose high barriers to entry and significant costs, new collaboration…
Manufacturing & Supply Chain
Pharma industry insiders view vaccines as one of the most challenging products to manufacture, fundamentally due to the inherent biological variability of the pathogen itself, which is the starting block of any vaccine, as well as the resulting inherent variability of the biological raw materials and processes required in vaccine production. For this reason, the product is very much the process when it comes to vaccine manufacturing. This has also been attributed as one of the main reasons for the relative scarcity of vaccine players globally.
Securing Trust in the COVID-19 Supply Chain: From Development & Delivery to Acceptance & Administration
Scientists have come together in an unparalleled worldwide collaboration and sharing of data to advance a COVID-19 vaccine.[1] As rollouts…
Population Health: Access & AntiVax Challenges
Vaccines have been touted – and rightly so – as the most cost-effective health intervention after access to clean water. It is estimated by global health institutions that vaccines save at least three million lives every year. While tremendous progress has been made since the discovery…
Top Story
Exclusive interview with
UNICEF Supply Chain director
Eva Kadilli
“The biggest challenge for us is that while responding to the immediate crisis caused by the global pandemic, we still needed to continue and coordinate our responses to other emergencies”
eBook
Vaccines
Long dismissed as the backwaters of healthcare innovation, the tremendous value of vaccines – the single most cost-effective health intervention after clean water – made itself starkly clear in 2020, as the discovery of a novel coronavirus quickly exploded into a full-blown global pandemic that rages on still.
Top Interviews on PharmaBoardroom
See more about Vaccines
Contact us
+44 20 7867 3717 info@gamma.pharma.kalyna.dev
For media inquiries, please contact: media@gamma.pharma.kalyna.dev
Address
PharmaBoardroom Limited Lynton House, 7-12, Tavistock Square, London, United Kingdom, WC1H 9LT
